|
1
|
Screening and prostate-cancer mortality in a randomized European study.
|
N Engl J Med
|
2009
|
35.94
|
|
2
|
Prostate-cancer mortality at 11 years of follow-up.
|
N Engl J Med
|
2012
|
16.91
|
|
3
|
Quality-of-life effects of prostate-specific antigen screening.
|
N Engl J Med
|
2012
|
7.21
|
|
4
|
Active surveillance for low-risk prostate cancer worldwide: the PRIAS study.
|
Eur Urol
|
2012
|
4.48
|
|
5
|
Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC).
|
Eur Urol
|
2009
|
3.42
|
|
6
|
Infectious complications and hospital admissions after prostate biopsy in a European randomized trial.
|
Eur Urol
|
2012
|
3.34
|
|
7
|
Radical prostatectomy for low-risk prostate cancer following initial active surveillance: results from a prospective observational study.
|
Eur Urol
|
2012
|
3.07
|
|
8
|
Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly.
|
Eur Urol
|
2008
|
2.92
|
|
9
|
A new and highly prognostic system to discern T1 bladder cancer substage.
|
Eur Urol
|
2011
|
2.68
|
|
10
|
Prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review.
|
Eur Urol
|
2008
|
2.66
|
|
11
|
A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range.
|
J Urol
|
2011
|
2.65
|
|
12
|
Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection.
|
Eur Urol
|
2010
|
2.47
|
|
13
|
Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer.
|
Eur Urol
|
2013
|
2.43
|
|
14
|
Does PSA velocity predict prostate cancer in pre-screened populations?
|
Eur Urol
|
2006
|
2.24
|
|
15
|
The effect of study arm on prostate cancer treatment in the large screening trial ERSPC.
|
Int J Cancer
|
2010
|
2.15
|
|
16
|
Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guérin treatment.
|
BJU Int
|
2010
|
2.14
|
|
17
|
The mutational landscape of prostate cancer.
|
Eur Urol
|
2013
|
2.14
|
|
18
|
Markers predicting response to bacillus Calmette-Guérin immunotherapy in high-risk bladder cancer patients: a systematic review.
|
Eur Urol
|
2011
|
2.11
|
|
19
|
A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer.
|
Eur Urol
|
2009
|
2.02
|
|
20
|
Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics.
|
Eur Urol
|
2007
|
2.02
|
|
21
|
Exosomes as biomarker treasure chests for prostate cancer.
|
Eur Urol
|
2010
|
1.94
|
|
22
|
Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).
|
Eur Urol
|
2008
|
1.94
|
|
23
|
Evolution of the androgen receptor pathway during progression of prostate cancer.
|
Cancer Res
|
2006
|
1.83
|
|
24
|
Truncated ETV1, fused to novel tissue-specific genes, and full-length ETV1 in prostate cancer.
|
Cancer Res
|
2008
|
1.68
|
|
25
|
Does local treatment of the prostate in advanced and/or lymph node metastatic disease improve efficacy of androgen-deprivation therapy? A systematic review.
|
Eur Urol
|
2010
|
1.66
|
|
26
|
Timing of curative treatment for prostate cancer: a systematic review.
|
Eur Urol
|
2013
|
1.63
|
|
27
|
Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
|
BJU Int
|
2012
|
1.62
|
|
28
|
Do anxiety and distress increase during active surveillance for low risk prostate cancer?
|
J Urol
|
2010
|
1.61
|
|
29
|
Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
|
Eur Urol
|
2008
|
1.58
|
|
30
|
Prospective validation of active surveillance in prostate cancer: the PRIAS study.
|
Eur Urol
|
2007
|
1.57
|
|
31
|
Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study.
|
BJU Int
|
2009
|
1.56
|
|
32
|
Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance.
|
Eur Urol
|
2006
|
1.54
|
|
33
|
A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC Rotterdam.
|
Eur Urol
|
2012
|
1.52
|
|
34
|
Anxiety and distress during active surveillance for early prostate cancer.
|
Cancer
|
2009
|
1.49
|
|
35
|
Pathological stage review is indicated in primary pT1 bladder cancer.
|
BJU Int
|
2009
|
1.46
|
|
36
|
hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.
|
Eur Urol
|
2007
|
1.45
|
|
37
|
Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit.
|
Eur J Cancer
|
2009
|
1.41
|
|
38
|
The long-term relationship between a real change in prostate volume and a significant change in lower urinary tract symptom severity in population-based men: the Krimpen study.
|
Eur Urol
|
2007
|
1.39
|
|
39
|
Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators.
|
Eur Urol
|
2011
|
1.29
|
|
40
|
Towards an optimal interval for prostate cancer screening.
|
Eur Urol
|
2011
|
1.27
|
|
41
|
Crystals cause acute necrotic cell death in renal proximal tubule cells, but not in collecting tubule cells.
|
Kidney Int
|
2005
|
1.24
|
|
42
|
Diagnostic value of OCT3/4 for pre-invasive and invasive testicular germ cell tumours.
|
J Pathol
|
2005
|
1.22
|
|
43
|
Discrimination between nontumor bladder tissue and tumor by Raman spectroscopy.
|
Anal Chem
|
2006
|
1.22
|
|
44
|
Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer.
|
Clin Cancer Res
|
2010
|
1.17
|
|
45
|
Predictors of unfavourable repeat biopsy results in men participating in a prospective active surveillance program.
|
Eur Urol
|
2011
|
1.16
|
|
46
|
Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
|
Eur Urol
|
2008
|
1.08
|
|
47
|
Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer.
|
J Urol
|
2010
|
1.07
|
|
48
|
Eleven-year outcome of patients with prostate cancers diagnosed during screening after initial negative sextant biopsies.
|
Eur Urol
|
2009
|
1.05
|
|
49
|
The FGFR3 mutation is related to favorable pT1 bladder cancer.
|
J Urol
|
2011
|
1.03
|
|
50
|
Immunotherapy for superficial bladder cancer.
|
Cancer Immunol Immunother
|
2004
|
1.03
|
|
51
|
Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer.
|
Eur Urol
|
2011
|
1.02
|
|
52
|
Hyaluronan is apically secreted and expressed by proliferating or regenerating renal tubular cells.
|
Kidney Int
|
2005
|
1.00
|
|
53
|
The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour.
|
J Pathol
|
2009
|
1.00
|
|
54
|
A methylation assay for the detection of non-muscle-invasive bladder cancer (NMIBC) recurrences in voided urine.
|
BJU Int
|
2011
|
1.00
|
|
55
|
Bladder cancer biomarkers and their role in surveillance and screening.
|
Int J Urol
|
2009
|
1.00
|
|
56
|
Prospective multicenter evaluation of the Beckman Coulter Prostate Health Index using WHO calibration.
|
J Urol
|
2012
|
1.00
|
|
57
|
An inventory of shedding data from clinical gene therapy trials.
|
J Gene Med
|
2007
|
1.00
|
|
58
|
A 3-plex methylation assay combined with the FGFR3 mutation assay sensitively detects recurrent bladder cancer in voided urine.
|
Clin Cancer Res
|
2013
|
0.99
|
|
59
|
The human PC346 xenograft and cell line panel: a model system for prostate cancer progression.
|
Eur Urol
|
2006
|
0.99
|
|
60
|
Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers.
|
Eur Urol
|
2012
|
0.98
|
|
61
|
Evaluation of diffusion-weighted MR imaging at inclusion in an active surveillance protocol for low-risk prostate cancer.
|
Invest Radiol
|
2013
|
0.97
|
|
62
|
Development and clinical validation of a real-time PCR assay for PITX2 DNA methylation to predict prostate-specific antigen recurrence in prostate cancer patients following radical prostatectomy.
|
J Mol Diagn
|
2012
|
0.96
|
|
63
|
Adenovirus-derived vectors for prostate cancer gene therapy.
|
Hum Gene Ther
|
2010
|
0.95
|
|
64
|
A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues.
|
Eur J Nucl Med Mol Imaging
|
2010
|
0.95
|
|
65
|
Gleason score 7 screen-detected prostate cancers initially managed expectantly: outcomes in 50 men.
|
BJU Int
|
2009
|
0.94
|
|
66
|
Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.
|
BJU Int
|
2011
|
0.93
|
|
67
|
False-negative prostate needle biopsies: frequency, histopathologic features, and follow-up.
|
Am J Surg Pathol
|
2010
|
0.93
|
|
68
|
Oxalate is toxic to renal tubular cells only at supraphysiologic concentrations.
|
Kidney Int
|
2005
|
0.92
|
|
69
|
Validation of the Urogenital Distress Inventory (UDI-6) and Incontinence Impact Questionnaire (IIQ-7) in a Dutch population.
|
Neurourol Urodyn
|
2013
|
0.92
|
|
70
|
Impacts of a population-based prostate cancer screening programme on excess total mortality rates in men with prostate cancer: a randomized controlled trial.
|
J Med Screen
|
2013
|
0.92
|
|
71
|
Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer.
|
BJU Int
|
2012
|
0.91
|
|
72
|
Psychological aspects of active surveillance.
|
Curr Opin Urol
|
2012
|
0.91
|
|
73
|
Clinical adenoviral gene therapy for prostate cancer.
|
Hum Gene Ther
|
2010
|
0.91
|
|
74
|
Optimization of nonmuscle invasive bladder cancer recurrence detection using a urine based FGFR3 mutation assay.
|
J Urol
|
2011
|
0.91
|
|
75
|
A longitudinal study on the impact of active surveillance for prostate cancer on anxiety and distress levels.
|
Psychooncology
|
2014
|
0.89
|
|
76
|
Prostate-specific antigen screening can be beneficial to younger and at-risk men.
|
CMAJ
|
2012
|
0.88
|
|
77
|
Prediction of prostate cancer in unscreened men: external validation of a risk calculator.
|
Eur J Cancer
|
2010
|
0.87
|
|
78
|
Body mass index as a prognostic marker for biochemical recurrence in Dutch men treated with radical prostatectomy.
|
BJU Int
|
2009
|
0.87
|
|
79
|
Prognostic factors for and outcome of locally advanced prostate cancer after radical prostatectomy.
|
BJU Int
|
2009
|
0.87
|
|
80
|
Excess all-cause mortality in the evaluation of a screening trial to account for selective participation.
|
J Med Screen
|
2013
|
0.86
|
|
81
|
Can non-malignant biopsy features identify men at increased risk of biopsy-detectable prostate cancer at re-screening after 4 years?
|
BJU Int
|
2007
|
0.86
|
|
82
|
Rotterdam randomized pilot studies of screening for prostate cancer--an overview after 10 years.
|
J Natl Cancer Inst
|
2005
|
0.85
|
|
83
|
Histopathological characteristics of lymph node metastases predict cancer-specific survival in node-positive prostate cancer.
|
BJU Int
|
2008
|
0.85
|
|
84
|
Informed decision making on PSA testing for the detection of prostate cancer: an evaluation of a leaflet with risk indicator.
|
Eur J Cancer
|
2010
|
0.84
|
|
85
|
Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial*.
|
BJU Int
|
2012
|
0.84
|
|
86
|
Compliance with biopsy recommendations of a prostate cancer risk calculator.
|
BJU Int
|
2011
|
0.84
|
|
87
|
Can dutasteride delay or prevent the progression of prostate cancer in patients with biochemical failure after radical therapy? Rationale and design of the Avodart after Radical Therapy for Prostate Cancer Study.
|
BJU Int
|
2009
|
0.84
|
|
88
|
Differential expression of protease activity in serum samples of prostate carcinoma patients with metastases.
|
Proteomics
|
2010
|
0.83
|
|
89
|
The additional value of TGFβ1 and IL-7 to predict the course of prostate cancer progression.
|
Cancer Immunol Immunother
|
2011
|
0.82
|
|
90
|
Prostate cancer in the Swedish section of ERSPC--evidence for less metastases at diagnosis but not for mortality reduction.
|
Eur Urol
|
2006
|
0.82
|
|
91
|
Disease-specific mortality may underestimate the total effect of prostate cancer screening.
|
J Med Screen
|
2010
|
0.82
|
|
92
|
Active surveillance: oncologic outcome.
|
Curr Opin Urol
|
2013
|
0.81
|
|
93
|
The value of EZH2, p27(kip1), BMI-1 and MIB-1 on biopsy specimens with low-risk prostate cancer in selecting men with significant prostate cancer at prostatectomy.
|
BJU Int
|
2009
|
0.81
|
|
94
|
A prostate cancer vaccine comprising whole cells secreting IL-7, effective against subcutaneous challenge, requires local GM-CSF for intra-prostatic efficacy.
|
Cancer Immunol Immunother
|
2008
|
0.81
|
|
95
|
Critical assessment of prebiopsy parameters for predicting prostate cancer metastasis and mortality.
|
Can J Urol
|
2011
|
0.80
|
|
96
|
Profiling of antibody production against xenograft-released proteins by protein microarrays discovers prostate cancer markers.
|
J Proteome Res
|
2011
|
0.80
|
|
97
|
Sonography, CT, and MRI of giant cavernous hemangioma of the kidney: correlation with pathologic findings.
|
AJR Am J Roentgenol
|
2004
|
0.80
|
|
98
|
Tumor protection by IL-7 secreting whole cell vaccine is merely mediated by NK1.1-positive cells.
|
J Immunother
|
2012
|
0.80
|
|
99
|
Nitroreductase-based therapy of prostate cancer, enhanced by raising expression of heat shock protein 70, acts through increased anti-tumour immunity.
|
Cancer Immunol Immunother
|
2005
|
0.80
|
|
100
|
T cell activation upon exposure to patient-derived tumor tissue: a functional assay to select patients for adoptive T cell therapy.
|
J Immunol Methods
|
2010
|
0.79
|
|
101
|
Reply from authors re: Michael Baum. Screening for prostate cancer: can we learn from the mistakes of the breast screening experience? Eur Urol 2013;64:540-1: screening for prostate cancer: we have learned and are still learning.
|
Eur Urol
|
2013
|
0.79
|
|
102
|
High-dose-rate brachytherapy and external-beam radiotherapy for hormone-naïve low- and intermediate-risk prostate cancer: a 7-year experience.
|
Int J Radiat Oncol Biol Phys
|
2012
|
0.79
|
|
103
|
Sexual function with localized prostate cancer: active surveillance vs radical therapy.
|
BJU Int
|
2012
|
0.79
|
|
104
|
Should prostate-specific antigen screening be offered to asymptomatic men?
|
Expert Rev Anticancer Ther
|
2010
|
0.79
|
|
105
|
Identifying and characterizing "escapes"-men who develop metastases or die from prostate cancer despite screening (ERSPC, section Rotterdam).
|
Int J Cancer
|
2011
|
0.78
|
|
106
|
Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: results of a randomized trial.
|
World J Urol
|
2013
|
0.78
|
|
107
|
Serum levels of arachidonic acid metabolites change during prostate cancer progression.
|
Prostate
|
2014
|
0.77
|
|
108
|
Gene transfer vectors targeted to human prostate cancer: do we need better preclinical testing systems?
|
Hum Gene Ther
|
2010
|
0.77
|
|
109
|
Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
|
Eur Urol
|
2011
|
0.77
|
|
110
|
Preclinical safety assessment of Ad[I/PPT-E1A], a novel oncolytic adenovirus for prostate cancer.
|
Hum Gene Ther Clin Dev
|
2014
|
0.76
|
|
111
|
Gene therapy in The Netherlands: highlights from the Low Countries.
|
J Gene Med
|
2007
|
0.75
|
|
112
|
[Early detection of prostate cancer--recommendations after 13 years of follow-up in the European randomised study].
|
Ned Tijdschr Geneeskd
|
2015
|
0.75
|
|
113
|
Reply from authors re: Brant A. Inman, Michael R. Abern. Interpreting a study on bladder cancer screening. Eur Urol 2013;64:48-50: the goal of cancer screening: early evaluation of screening for bladder cancer.
|
Eur Urol
|
2013
|
0.75
|
|
114
|
Pre-clinical safety assessment of Ad[I/PPT-E1A], a novel oncolytic adenovirus for prostate cancer.
|
Hum Gene Ther Clin Dev
|
2014
|
0.75
|
|
115
|
A small chimeric promoter for high prostate-specific transgene expression from adenoviral vectors.
|
Prostate
|
2007
|
0.75
|
|
116
|
Prospective validation of a risk calculator which calculates the probability of a positive prostate biopsy in a contemporary clinical cohort.
|
Eur J Cancer
|
2012
|
0.75
|
|
117
|
[MRI/US-fusion for targeted prostate biopsy].
|
Ned Tijdschr Geneeskd
|
2014
|
0.75
|
|
118
|
Digital rectal examination is no longer necessary in the routine follow-up of men with undetectable prostate specific antigen after radical prostatectomy: the implications for follow-up.
|
Eur Urol
|
2005
|
0.75
|
|
119
|
Overestimation of prostate cancer mortality and other-cause mortality by the Kaplan-Meier method.
|
Can J Urol
|
2013
|
0.75
|
|
120
|
Comparison of two assays for human kallikrein 2.
|
Clin Chem
|
2003
|
0.75
|
|
121
|
Disease-specific and patient-reported outcomes under active surveillance.
|
Curr Opin Urol
|
2015
|
0.75
|